Date: 2016-04-25
Type of information: Submission of a clinical trial application
phase: 1
Announcement: submission of a clinical trial application
Company: Tesaro (US - MA)
Product: TSR-022
Action
mechanism: monoclonal antibody. TSR-022 is a monoclonal antibody candidate targeting TIM-3 and was developed as part of a collaboration between TESARO and AnaptysBio. This collaboration was initiated in March of 2014, and is focused on the development of monospecific antibody drug candidates targeting PD-1 (TSR-042), TIM-3 (TSR-022), and LAG-3, and bi-specific antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3, in addition to a novel bispecific antibody candidate designed to target undisclosed targets.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 25, 2016, Tesaro announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the FDA. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3. Following clearance of the IND, Tesaro plans to begin a Phase 1 study in mid-2016.
